Analysts Reports (Imugene), page-67

Received this in my in tray this morning...

Bringing together experts from Novartis, BMS, Autolus, and the University of Pennsylvania

No images? Click here

Reengineering CAR-T for solid tumors
Webinar
THU, MAY 27, 2:00PM ET
REGISTER NOW
CAR-Ts revolutionized the way blood cancers can be treated, but still haven’t really caught on in the market as physicians and patients consider vein-to-vein times, cost and manufacturing snafus. Now a large group of scientists are leading a well-funded drive to adapt this technology for solid tumors, while making the whole process much more economical for patients and payers. The winners will help revolutionize the field. And the race to be first has inspired a furious sprint to the finish line.



EXCLUSIVE SPONSOR



OUR PRESENTERS


Jennifer Brogdon
Executive Director, Head of Cell Therapy Research, Department of Exploratory Immuno-Oncology
NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH (NIBR)


Martin Pule
Senior Vice President, Founder and Chief Scientific Officer
AUTOLUS


Teri Foy
Senior Vice President, Research and Early Development Immuno-Oncology and Cell Therapy
BRISTOL MEYERS SQUIBB



Donald O'Rourke
Professor in the Department of Neurosurgery
UNIVERSITY OF PENNSYLVANIA



MODERATED BY

Kyle Blankenship
Senior Editor
ENDPOINTS NEWS




REGISTER NOW


Designed by


Interested in sponsoring your own webinar?
Contact Mike Peck at [email protected]

Upgrade to a paid subscription.



Forward
Sent from Endpoints News, 2029 Becker Drive, Lawrence, KS 66047

This is a sponsored email for Endpoints News subscribers. You may opt-out of sponsored emails by upgrading to a paid Insider subscription.

Unsubscribe entirely from all news and sponsored posts by clicking the link below:
Unsubscribe